A number of EU member states have a vaccination strategy for a second dose of COVID-19 vaccine that is different from the one used for the first dose. For example, some EU citizens can receive their first dose of Vaxzevria and a second dose of Comirnaty. In this case, we are talking about heterologous vaccination (sometimes called “mixed vaccination”).
Luxembourg is not yet implementing this strategy as part of its vaccination campaign at this stage, although a recommendation from the European Medicines Agency (EMA) is expected, in principle, by the end of June, at this time. The agency is currently analyzing data from various studies and will take a position as soon as this analysis is completed. Preliminary results from studies in Spain and Germany indicate a satisfactory immune response. More data is expected soon, including the COM-COV and COM-COV-2 studies, which examine a series of vaccination schedules in which different vaccines are administered for the first and second dose.
As soon as the position of the EMA becomes known, the government will advise whether the vaccination strategy needs to be adapted. Meanwhile, the introduction of a particular type of vaccine is subject to an individual assessment by a doctor, taking into account the state of health of the person invited for vaccination. For people with a history of thromboembolism with heparin-induced thrombocytopenia (HITT or HIT type 2), for whom a 2nd dose of the same vaccine is contraindicated, the vaccination schedule can be supplemented with a dose of Comirnaty with a delay of 8 to 12 weeks, or as soon as the clinical condition permits …
Luxembourg is placing particular emphasis on enhanced surveillance of the safety and efficacy of COVID-19 vaccines through the national notification system and is applying all means to ensure the safety and effectiveness of the vaccination campaign while ensuring widespread immunization coverage.
Reported by the Ministry of Health